| http://www.w3.org/ns/prov#value | - An agonist can include soluble forms of DR5 and monoclonal antibodies directed against the DR5 polypeptide. [0660] In a further aspect, the present invention is directed to a method for inhibiting apoptosis induced by a TNF-family ligand, which involves administering to a cell which expresses the, DR5 polypeptide an effective amount of an antagonist capable of decreasing DR5 mediated signaling.
|
